Cue Biopharma (CUE) Competitors $0.80 -0.02 (-2.66%) Closing price 03:58 PM EasternExtended Trading$0.82 +0.01 (+1.49%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. TKNO, SCPH, ALLO, SGMT, SOPH, AARD, FENC, TLSA, GALT, and ALECShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), Galectin Therapeutics (GALT), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Tiziana Life Sciences Galectin Therapeutics Alector Alpha Teknova (NASDAQ:TKNO) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment. Do analysts recommend TKNO or CUE? Alpha Teknova currently has a consensus target price of $10.00, suggesting a potential upside of 123.31%. Given Alpha Teknova's stronger consensus rating and higher probable upside, research analysts plainly believe Alpha Teknova is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Teknova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, TKNO or CUE? Alpha Teknova has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Does the media favor TKNO or CUE? In the previous week, Cue Biopharma had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for Cue Biopharma and 0 mentions for Alpha Teknova. Cue Biopharma's average media sentiment score of 1.00 beat Alpha Teknova's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Alpha Teknova Neutral Cue Biopharma Positive Is TKNO or CUE more profitable? Alpha Teknova has a net margin of -55.24% compared to Cue Biopharma's net margin of -469.35%. Alpha Teknova's return on equity of -26.51% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Alpha Teknova-55.24% -26.51% -18.40% Cue Biopharma -469.35%-230.13%-111.16% Which has better valuation and earnings, TKNO or CUE? Alpha Teknova has higher revenue and earnings than Cue Biopharma. Alpha Teknova is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlpha Teknova$37.74M6.35-$26.75M-$0.42-10.66Cue Biopharma$8.29M7.46-$40.67M-$0.56-1.44 Do insiders and institutionals hold more shares of TKNO or CUE? 13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by company insiders. Comparatively, 10.8% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryAlpha Teknova beats Cue Biopharma on 11 of the 17 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.78M$3.06B$5.75B$9.73BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.4420.9930.2525.89Price / Sales7.46387.70474.39123.10Price / CashN/A43.2325.7828.79Price / Book2.879.639.426.00Net Income-$40.67M-$54.08M$3.27B$265.29M7 Day Performance-1.81%2.70%2.08%2.59%1 Month Performance-8.94%4.14%3.63%0.98%1 Year Performance4.48%9.46%30.13%18.75% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma2.9478 of 5 stars$0.80-2.7%N/A+7.3%$61.78M$8.29M-1.4460TKNOAlpha Teknova1.6521 of 5 stars$4.41-6.0%$10.00+126.8%-4.8%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.5245 of 5 stars$4.78+3.9%$14.00+192.9%-9.7%$245.17M$49.97M-2.6430News CoveragePositive NewsGap UpTrading HaltedALLOAllogene Therapeutics2.6204 of 5 stars$1.09-0.9%$8.44+674.7%-54.4%$244.07M$20K-0.98310SGMTSagimet Biosciences2.826 of 5 stars$7.55-1.6%$25.67+240.0%+141.8%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9261 of 5 stars$3.49+0.6%$8.00+129.2%-3.5%$234.50M$65.17M-7.93520Positive NewsAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018FENCAdherex Technologies1.9304 of 5 stars$8.20-1.9%$13.33+62.6%+51.9%$232.52M$47.54M-19.5210News CoverageAnalyst RevisionTLSATiziana Life Sciences0.5423 of 5 stars$1.89-4.1%N/A+68.9%$230.19MN/A0.008GALTGalectin Therapeutics2.3987 of 5 stars$3.90+9.2%$6.00+53.8%+77.5%$228.70MN/A-6.099ALECAlector3.8716 of 5 stars$2.13-5.3%$4.17+95.6%-52.5%$227.73M$100.56M-1.84270 Related Companies and Tools Related Companies Alpha Teknova Alternatives scPharmaceuticals Alternatives Allogene Therapeutics Alternatives Sagimet Biosciences Alternatives SOPHiA GENETICS Alternatives Aardvark Therapeutics Alternatives Adherex Technologies Alternatives Tiziana Life Sciences Alternatives Galectin Therapeutics Alternatives Alector Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access